Print

Spectrum Pharmaceuticals, Inc. (SPPI) Completes Acquisition of Allos Therapeutics, Inc. (ALTH); Effective and Swift Integration Expected to Result in Significant Synergies  
9/6/2012 10:04:03 AM

HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology today announced the successful completion of the acquisition of Allos Therapeutics, Inc. (NasdaqGS: ALTH) (Allos), on September 5, 2012 through a “short-form” merger of Sapphire Acquisition Sub, Inc., a wholly-owned subsidiary of Spectrum, with and into Allos with Allos surviving the merger and continuing as a wholly-owned subsidiary of Spectrum.
//-->